News Details

( As on 21/07/2025 08:26)

Sun Pharma. - Press Release

Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release, titled Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint.